An observational study in Cancer Pain, sponsored by Mundipharma (China) Pharmaceutical Co. Ltd. Not yet recruiting at 20 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Mundipharma (China) Pharmaceutical Co. Ltd (part of Mundipharma) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Cancer Pain by Mundipharma — 1 open to participants now, 1 under way, none of them phase 3. Cancer Pain · Mundipharma.
Among the 11 studies in Cancer Pain by Mundipharma, this one is the only one that started in 2026, is one of 2 observational ones, and was the 11th registered.
311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.
Browse Cancer Pain studies →1 of the 11 studies in Cancer Pain by Mundipharma is open now, in 1 country.
By country, each count listing its studies:
Of the 45 Cancer Pain studies recruiting now, 33 (73%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 378 is above the median of 151 across 61 observational studies indexed under Cancer Pain.
Median enrollment 128 across the 9 interventional studies, 231 across the 2 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Mundipharma (China) Pharmaceutical Co. Ltd, one of the names counted as Mundipharma. Under that name alone:
Mundipharma (China) Pharmaceutical Co. Ltd is the lead sponsor of 19 studies on the registry; 1 is open to participants now.
1 of the studies in Cancer Pain by Mundipharma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07869797Mundipharma (China) Pharmaceutical Co. LtdReal-world Study of the Effectiveness and Tolerability of Outpatient Titration of OxyContin for the Moderate and Severe Pain in Cancer Patients | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Cancer Pain by Mundipharma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this observational study is to evaluate the effectiveness and tolerability of outpatient titration regimen with OxyContin as background for moderate and severe pain in cancer patients in adult patients with moderate to severe cancer pain. The main questions it aims to answer are
Primary Endpoints: The proportion of participants achieving pain remission, which is defined as the rate of participants with average NRS (Numerical rating scale) score ≤3 [CR (Complete remission)] or achieving a reduction of 25% when NRS score >3 [PR (Partial remission)] at 72 h.
Secondary Endpoints:
Adult patients with moderate-to-severe cancer pain treated with the outpatient OxyContin dose titration regimen,able to complete questionnaire and scale assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Outpatient OxyContin Dose Titration for Patients with Moderate-to-Severe Cancer Pain,This study is a multi-center prospective single arm real-world study with OxyContin as background titration. The study consists of 2 phases: Screening/ titration phase and maintenance phase.
The proportion of participants achieving pain relief after treatment.
Pain assessments will be performed using the BPI-SF (Brief Pain Inventory-Short Form) and NRS (Numerical Rating Scale). The proportion of participants achieving pain remission, which is defined as the rate of participants with average NRS (Numerical rating scale) score ≤3 \[CR (Complete remission)\] or achieving a reduction of 25% when NRS score \>3 \[PR (Partial remission)\] at 72 h
Time frame: From enrollment to the end of follow-up at Day 8.
Adverse events: the frequency and severity of adverse events
assessed primarily by adverse events occurring after treatment (defined as adverse events that emerge or worsen following the first dose of OxyContin), and may also be evaluated via physical examinations and vital signs.
Time frame: From enrollment to the end of follow-up at Day 8.
Plan to share: No — Individual participant data (IPD) will not be shared with other researchers, due to privacy protection and ethical considerations. Study results may be published in the form of aggregated summary data.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Apr 2027, 6 months later.
Of 26 observational studies under Cancer Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 40. This study's planned 6 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mundipharma (China) Pharmaceutical Co. Ltd →